These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 19090867)

  • 21. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
    Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P
    J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
    Hörl WH; Vanrenterghem Y; Canaud B; Mann J; Teatini U; Wanner C; Wikström B
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii25-32. PubMed ID: 15824127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A strategy to reduce inflammation and anemia treatment's related costs in dialysis patients.
    Di Iorio BR; Di Micco L; Russo L; Nardone L; De Simone E; Sirico ML; Di Natale G; Russo D
    G Ital Nefrol; 2018 Feb; 35(1):. PubMed ID: 29390245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is it time to reconsider subcutaneous administration of epoetin?
    Patel TV; Robinson K; Singh AK
    Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing anemia management in hospitalized patients with end-stage renal disease.
    Heung M; Mueller BA; Segal JH
    Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs.
    Hörbrand F; Rottenkolber D; Fischaleck J; Hasford J
    Gesundheitswesen; 2014 Nov; 76(11):e79-84. PubMed ID: 24493578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease.
    Papatheofanis F; Bookhart BK; Muser E; Piech CT
    J Occup Environ Med; 2008 May; 50(5):584-9. PubMed ID: 18469628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilar epoetin zeta in nephrology - a single-dialysis center experience.
    Lonnemann G; Wrenger E
    Clin Nephrol; 2011 Jan; 75(1):59-62. PubMed ID: 21176751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achieving therapeutic targets in renal anaemia: considering cost-efficacy.
    Deray G
    Curr Med Res Opin; 2004 Jul; 20(7):1095-101. PubMed ID: 15265254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare resource utilization for anemia management: current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A.
    Saueressig U; Kwan JT; De Cock E; Sapède C
    Blood Purif; 2008; 26(6):537-46. PubMed ID: 18997465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of the impact of weekly versus monthly erythropoiesis stimulating protein therapy on patients with CKD and their families.
    Globe D; Glidden D; Hertel J; Thomas J; Ackerman M; Chidolue F; Blanco B; Borden A; Goss TF; Xu X; Kewalramani R
    Nephrol Nurs J; 2007; 34(2):151-61. PubMed ID: 17486946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients.
    Aspinall SL; Smith KJ; Good CB; Zhao X; Stone RA; Tonnu-Mihara IQ; Cunningham FE
    Appl Health Econ Health Policy; 2013 Dec; 11(6):653-60. PubMed ID: 24092553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [How to analyze and prevent the risks associated with the use of erythropoiesis stimulating agents].
    Dussert S; Ferrandini C; Hurot JM; Magnam J; Ortiz JP
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S256-60. PubMed ID: 17373267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time Savings with Once-Monthly C.E.R.A.: A Time and Motion Study Conducted in 13 Haemodialysis Centres in Italy.
    De Cock E; Kritikou P; Ravera S; Filippini A
    Blood Purif; 2015; 40(2):173-9. PubMed ID: 26303977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care.
    Schiller B; Besarab A
    Curr Med Res Opin; 2011 Aug; 27(8):1539-50. PubMed ID: 21682552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients.
    Courtney AE; McNamee PT; Maxwell AP
    Nephron Clin Pract; 2007; 107(1):c14-9. PubMed ID: 17664890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
    Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
    J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost savings using a protocol approach to manage anemia in a hemodialysis unit.
    Charlesworth EC; Richardson RM; Battistella M
    Am J Nephrol; 2014; 39(6):509-14. PubMed ID: 24903565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Direct medical cost of erythropoiesis-stimulating agents in anaemia treatment of chronic renal failure patient: a literature review].
    Ranchon F; Hédoux S; Laville M; Fouque D; Decullier E; Chapuis F; Huot L
    Nephrol Ther; 2010 Apr; 6(2):97-104. PubMed ID: 20097148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.